India markets close in 5 hours 49 minutes

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
23.30+0.56 (+2.46%)
As of 11:56AM CST. Market open.
Full screen
Previous close22.74
Open22.80
Bid23.28 x N/A
Ask23.30 x N/A
Day's range22.72 - 23.45
52-week range14.87 - 30.69
Volume4,169,844
Avg. volume11,897,630
Market cap31.795B
Beta (5Y monthly)0.50
PE ratio (TTM)26.57
EPS (TTM)0.88
Earnings date30-Apr-2020
Forward dividend & yield0.18 (0.79%)
Ex-dividend date01-Jul-2020
1y target est25.60
  • Hepalink Announces Exciting Regulatory Developments
    Business Wire

    Hepalink Announces Exciting Regulatory Developments

    Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399, HKEx: 9989), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced exciting regulatory milestones in both the marketed pharmaceutical business and its pipeline development.

  • Hepalink Announces the Appointment of Healthcare Senior Executive Mr. Frank Sun as Executive Director and Vice Chairman of the Board
    Business Wire

    Hepalink Announces the Appointment of Healthcare Senior Executive Mr. Frank Sun as Executive Director and Vice Chairman of the Board

    Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced the appointment of Mr. Frank Sun as Executive Director and the election of Mr. Sun as the Vice Chairman of the Board. Mr. Sun will work with the Board on strategy design, enhancement and implementation, and lead the efforts in strategic investment, capital markets, and the development of Hepalink’s innovative businesses globally.